235 related articles for article (PubMed ID: 26855592)
1. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.
Xu H; Tian Y; Yuan X; Liu Y; Wu H; Liu Q; Wu GS; Wu K
Onco Targets Ther; 2016; 9():431-44. PubMed ID: 26855592
[TBL] [Abstract][Full Text] [Related]
2. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.
Xu H; Wu K; Tian Y; Liu Q; Han N; Yuan X; Zhang L; Wu GS; Wu K
Int J Oncol; 2016 Oct; 49(4):1343-50. PubMed ID: 27499099
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis.
Li Z; Yin S; Zhang L; Liu W; Chen B; Xing H
Onco Targets Ther; 2017; 10():859-870. PubMed ID: 28243121
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.
Jang MH; Kang HJ; Jang KS; Paik SS; Kim WS
Oncol Lett; 2016 Oct; 12(4):2728-2733. PubMed ID: 27698848
[TBL] [Abstract][Full Text] [Related]
5. Role of CD44 in breast cancer.
Al-Othman N; Alhendi A; Ihbaisha M; Barahmeh M; Alqaraleh M; Al-Momany BZ
Breast Dis; 2020; 39(1):1-13. PubMed ID: 31839599
[TBL] [Abstract][Full Text] [Related]
6. DACH1 suppresses breast cancer as a negative regulator of CD44.
Xu H; Yu S; Yuan X; Xiong J; Kuang D; Pestell RG; Wu K
Sci Rep; 2017 Jun; 7(1):4361. PubMed ID: 28659634
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
9. CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.
Zhou J; Du Y; Lu Y; Luan B; Xu C; Yu Y; Zhao H
Front Oncol; 2019; 9():802. PubMed ID: 31497537
[No Abstract] [Full Text] [Related]
10. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
11. EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival.
Xu H; Jiao Y; Yi M; Zhao W; Wu K
Front Oncol; 2019; 9():26. PubMed ID: 30761270
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.
Lin J; Ding D
Cancer Cell Int; 2017; 17():8. PubMed ID: 28070170
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis.
Wang Z; Wang Q; Wang Q; Wang Y; Chen J
Int J Biol Markers; 2017 Mar; 32(1):e75-e82. PubMed ID: 27470135
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
16. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
[TBL] [Abstract][Full Text] [Related]
17. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
18. CD44
Wang H; Wang L; Song Y; Wang S; Huang X; Xuan Q; Kang X; Zhang Q
Oncol Lett; 2017 Nov; 14(5):5890-5898. PubMed ID: 29113223
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis.
Wang Z; Tang Y; Xie L; Huang A; Xue C; Gu Z; Wang K; Zong S
Front Oncol; 2019; 9():309. PubMed ID: 31114754
[No Abstract] [Full Text] [Related]
20. Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.
Shi YY; Jiang H
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
